S&P: Gilead Sciences notes A-

Standard & Poor’s said it assigned an A- rating to Gilead Sciences Inc.’s proposed senior unsecured notes offering.

The proceeds will be used for general corporate purposes.

After the transaction closes, leverage metrics will remain firmly consistent with its minimal financial risk profile, S&P said.

The company’s A- corporate credit rating continues to reflect its satisfactory business risk profile, supported by the company’s longtime industry leading portfolio of HIV treatments and fast growing sales of Sovaldi, the agency said.

However, Gilead’s high concentration in the HIV and liver therapeutic categories somewhat limits its business risk score, S&P said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.